US Markets

Health Care Sector Update for 12/05/2019: AKER,PDCO,AUPH,SAGE

Top Health Care Stocks

JNJ +0.24%

PFE -0.21%

ABT +0.15%

MRK -0.01%

AMGN -0.20%

Health care stocks were edging higher, with the NYSE Health Care Index climbing almost 0.1% while the shares of health care companies in the S&P 500 also were down just over 0.1% as a group. The Nasdaq Biotechnology index was falling almost 1.3%.

Among health care stocks moving on news:

(-) Akers Biosciences (AKER) dropped 45% to a worst-ever $3.03 per share after the rapid health information technologies Thursday priced an $8 million public offering of 1.99 million common shares at $4 apiece, representing a 27.3% discount to Wednesday's closing price. Investors also received one warrant to buy one Series C convertible preferred share, also exercisable at $4 each, for each common share they purchased.

In other sector news:

(+) Aurinia Pharmaceuticals (AUPH) more than doubled in price at one point early Thursday, climbing 108% to a best-ever $17.48 a share, after saying a combination of its Voclosporin drug candidate and mycophenolate and low-dose corticosteroids produced a 40.8% renal response rate in patients with lupus nephritis compared with a 22.5% response rate in patients in the control group during a phase III trial.

(+) Patterson Cos (PDCO) climbed 14% after the dental and animal-health products distributor reported a better-than-expected non-GAAP Q2 profit and announced an agreement in principle with federal prosecutors in a probe of alleged improper sales by its Animal Health International unit. Under terms of the proposed deal, the company will pay $52.8 million in fines and forfeitures and will plead guilty to a strict-liability misdemeanor in exchange for a non-prosecution agreement by the US Attorney's Office in western Virginia.

(-) Sage Therapeutics (SAGE) slumped Thursday, falling as much as 62% to its lowest share price since February 2017, after reporting disappointing results from phase III testing of its SAGE-217 drug candidate to treat major depressive disorder, failing to achieve the primary endpoint of a statistically significant reduction in patient symptoms compared with a placebo.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

AKER PDCO AUPH SAGE

Latest Markets Videos